Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the Laser Device Business, sales of high-power lasers and quantum-dot lasers increased, while sales of DFB lasers and compact visible lasers declined due to lower demand and other factors. In the Laser and Optical Solutions Business, sales in the retinal projection product business declined due to the voluntary recall and other factors, while development contract revenue increased 28.0%.
None. The notes regarding the going concern assumption state, “There are no applicable matters.”
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥1,372 million (YoY +4.9%) |
| Operating profit | ¥-326 million |
| Ordinary income | ¥-305 million |
| Profit attributable to owners of the parent | ¥-357 million |
| Net income per share | △¥8.55 |
| Operating Margin | -23.8% |
| Equity ratio | End of the current fiscal period 87.9% / End of previous period 94.8% |
| Total assets | ¥5,565 million |
| Net assets | ¥4,900 million |
| Cash flows from operating activities | ¥-481 million |
| Cash flows from investing activities | ¥-886 million |
| Cash flows from financing activities | ¥355 million |
| Cash and cash equivalents at end of period | ¥2,741 million |
| Full-year earnings forecast | Net Sales ¥1,850 million (YoY +34.8%) / Operating profit ¥3 million / Ordinary income ¥3 million / Net income ¥-58 million |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Segment revenue | Laser Device Business ¥1,173,248 thousand (YoY +4.7%), Laser and Optical Solutions Business ¥199,552 thousand (YoY +6.1%) |
| Segment profit | Laser Device Business ¥128,212 thousand (YoY -9.2%), Laser and Optical Solutions Business ¥-135,781 thousand |
| Depreciation and amortization | ¥98,223 thousand |
| Impairment loss | ¥5,841 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Head office relocation costs ¥43,772 thousand, Impairment Losses ¥5,841 thousand, Impairment Losses on Shares of Affiliates ¥1,363 thousand |
| Disclosure regarding the going concern assumption | None. The notes regarding the going concern assumption state, “There are no applicable matters.” |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | The company resolved to submit to the annual general meeting of shareholders scheduled for 24 June 2026 a capital policy under which ¥84,467 thousand of stated capital and ¥1,361,075 thousand of capital reserves would be reduced, with the full amount of the resulting ¥1,445,543 thousand increase in other capital surplus transferred to retained earnings. There will be no impact on net assets or financial results. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts, and for individual investors) |
| Issued Shares at Period-End | 41,840,875 |
| Treasury Shares at Period-End | 829 |
| Factors Behind Changes in Business Performance | In the Laser Device Business, sales of high-power lasers and quantum-dot lasers increased, while sales of DFB lasers and compact visible lasers declined due to lower demand and other factors. In the Laser and Optical Solutions Business, sales in the retinal projection product business declined due to the voluntary recall and other factors, while development contract revenue increased 28.0%. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Laser Device Business, sales of high-power lasers and quantum-dot lasers increased, while development contract revenue rose in the Laser and Optical Solutions Business. However, selling, general and administrative expenses exceeded gross profit as sales channels were being developed following the business restructuring and changes in sales policy. The retinal projection product business reported lower sales due to the voluntary recall of MEOCHECK and other factors.